Therapeutic immunization in HIV infection.

Area of Science:

• Immunology
• Virology
• Vaccinology

Background:

• Antiretroviral therapy (ART) is effective for HIV but has limitations like drug resistance, toxicity, and cost.
• Therapeutic immunization strategies are being explored to improve immunological control of HIV and reduce treatment duration.

Purpose of the Study:

• To review current strategies and findings in therapeutic immunization for HIV.
• To evaluate the efficacy of different vaccine approaches in boosting HIV-specific T cell responses.

Main Methods:

• Review of clinical trials involving various vaccine platforms: inactivated virus particles, peptides, naked DNA, recombinant live vectors (e.g., HIV-recombinant canarypox), and dendritic cell infusions.
• Analysis of immune correlates of protection, focusing on T cell responses (CD4 and CD8).

Main Results:

• Boosting HIV-specific T cells, particularly effector and memory T cells, is a key goal.
• Trials with inactivated virus, peptides, or DNA showed moderate effects on viral replication, often needing adjuvants or combination therapy.
• Recombinant canarypox vectors demonstrated immunogenicity for HIV-specific CD4 and CD8 T cells.
• Significant viral control or prolonged treatment interruptions were observed in chronically ART-treated patients but not in acutely infected individuals.
• Autologous dendritic cell infusions showed promise in chronically infected patients.

Conclusions:

• Therapeutic immunization shows encouraging, albeit modest, results, particularly in chronic HIV infection.
• The differential efficacy between acute and chronic infection warrants further investigation.
• Development of more potent vaccine candidates is crucial for optimizing therapeutic immunization strategies against HIV.